Aleix Prat, MD, PhD
There are a number of novel treatments being developed in the paradigm of HER2-positive breast cancer, according to Aleix Prat, MD, PhD, head of the Department of Medical Oncology at the University of Barcelona.
In a lecture during the 2017 San Antonio Breast Cancer Symposium, Prat highlighted some of these systemic therapies, which include biosimilars, novel chemotherapy modalities, tyrosine kinase inhibitors (TKIs), and more.
A study investigating the efficacy and safety of the biosimilar ABP 980 compared with trastuzumab (Herceptin) in HER2-positive early-stage breast cancer showed clinical equivalence in the neoadjuvant setting. The results further demonstrated similarity between the drugs.
... to read the full story